Abstract
dc:description.abstractThe USA faces $220 billion economic loss and eighty thousand deaths per year due to alcohol abuse while affecting more than 15 million people, making it the third largest life-style related cause of death. The U.S. FDA has approved four medications namely, disulfiram, acamprosate, oral naltrexone, and injectable long-acting naltrexone. These existing drugs are trashed with side effects, have a low success rate, indicating a demand for new potential drugs. We studied the effects of the CB1 negative allosteric modulator, PSNCBAM-1, and the dopamine D4 receptor antagonist, L-745,870 in mouse models of alcohol addiction. PSNCBAM-1 did not significantly reduce CPP for 2.0 g/kg ethanol or alter locomotor activity, but its dose-dependently attenuated oral ethanol self-administration at the dose of 30 mg/kg. 18 and 30 mg/kg PSNCBAM-1 significantly reduced self-administration of palatable food reward. These results suggest, PSNCBAM-1 produces a non-specific anhedonic effect that may preclude its use in AUD. L-745,870 did not significantly affect conditioned place preference for 2.0 g/kg ethanol, ethanol self-administration, locomotor activity in an open field, or co-ordination in the rotarod test. These results suggest that D4R antagonism does not alter the rewarding value of ethanol.
Degree
thesis:*- Name thesis:degree_name
- M.S. Pharmaceutical Sciences
- Level thesis:degree_level
- Thesis
- Discipline thesis:degree_discipline
- Chemistry & Biochemistry
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Sumi, Mousumi Akter
- Contributors dc:contributor
-
- Keck, Thomas M.
- Grinias, James
- Fischer, Bradford D.
Subjects
dc:subject × 9Identifiers
dc:identifier.*- Repository record dc:identifier
- https://rdw.rowan.edu/etd/2863